Metastatic Her2-Positive Disease

San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more.

In a video interview, Nancy U. Lin, MD, discussed the DESTINY-Breast12 trial in progress presented at the virtual ESMO Congress.

Sara M. Tolaney, MD, MPH, discussed “unprecedented results” from DESTINY-Breast03 presented at the virtual ESMO Congress in a video interview with Healio.

In a video interview, Sara M. Tolaney, MD, MPH, discussed the currently enrolling DESTINY-Breast09 trial presented at the virtual ESMO Congress.